German Ophthalmological Society honors Uta Gehlsen with prestigious scientific award for her research on the use of semifluorinated alkanes in dry eye treatment

Heidelberg, Germany – October 2, 2017 – The German Ophthalmological Society (DOG) presented Uta Gehlsen, PhD, Ocular Surface Group, Department of Ophthalmology, University of Cologne, with the “Dry Eye and Blepharitis/MGD” Award for her research related to the use of a semifluorinated alkane (SFA F4H5) as a novel carrier for cyclosporine A for the topical…

Novaliq strengthens executive management team with the appointment of Gabriela Burian, MD, MPH, as consulting chief medical officer

NOVALIQ GmbH, a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, today announced the appointment of Gabriela Burian, MD, MPH, as Consulting Chief Medical Officer (CMO). Dr. Burian brings over 25 years of international clinical experience to the company. She is responsible for leading…

Novaliq conducts a first-in-class ocular neuropathic pain and anti-inflammatory cannabinoid drug development program in collaboration with the university of Cologne, germany

Novaliq GmbH, a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, today announced successful application of a first-in-class ocular neuropathic pain and anti-inflammatory cannabinoid-based dry eye disease (DED) treatment approach in collaboration with the University of Cologne, Germany. DED is one of the most…

Novaliq GmbH announces licensing agreement with AFT pharmaceuticals for the distribution of NovaTears®

Novaliq, a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, today announced a strategic licensing agreement with AFT Pharmaceuticals (AFT) for the commercialization of Novaliq’s lead product NovaTears® in Australia and New Zealand. NovaTears is Novaliq’s first commercially available ophthalmic product for the treatment…

Novaliq announces positive topline results of phase 2 clinical trial evaluating CyclASol® in adults with moderate to severe dry eye disease

Novaliq GmbH, a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective therapeutics for ophthalmology, today announced positive Phase 2 results evaluating CyclASol®, a clear, preservative-free cyclosporine A solution, in 207 patients with moderate to severe dry eye disease (DED). CyclASol showed a consistent reduction in corneal fluorescein…

Novaliq strengthens executive management team by appointing Christian Roesky (PHD, as chief executive officer)

Former B+L, Abbott and Alcon Executive To Lead Company Through Multiple Product Development, Clinical Trial, and Commercialization Programs Bernhard Günther, Co-founder of Novaliq, Named Chief Innovation Officer  Novaliq GmbH, a specialty pharmaceutical company with a disruptive drug delivery platform that transforms poorly soluble drugs into effective ocular therapeutics, today announced the appointment of Christian Roesky, PhD,…